RNAseq analysis of integrin ß3-mediated responses to in vitro docetaxel in PyMT-BO1 breast cancer cells

We sought to transcriptomically characterize the effect of integrin ß3 expression on breast cancer cell responses to the microtubule-inhibiting chemotherapeutic agent docetaxel. Experiments were performed in PyMT-BO1 murine breast cancer cells with CRISPR mediated deletion of the Itgb3 gene. Cells were subsequently retrovirally rescued using either an empty vector construct (pMx), a functional human integrin ß3 construct (hß3), or a signaling-deficient integrin ß3 mutant. Overall design: mRNA profiles from ß3KO PyMT-BO1 murine breast cancer cells rescued with empty vector (pMx), functional integrin ß3 (hß3), or signaling-deficient mutant integrin ß3 (?ß3) and receiving 24 hours of treatment with either DMSO or 10nM docetaxel. 3 biological replicates per treatment group.